Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
Dr Adam M Hill's latest post on why diagnostics are now getting the attention they deserve.
#diagnostics #Test #Covid_19 @Tech_Trender
Diagnostics: why are they now getting the attention they deserve?
A place where words matter
link.medium.com
Oncimmune's CSO Tariq Sethi discussing antibody testing- opportunity to understand cancer through immune system. They are working on point of care test for lung cancer. #CancerProgressNYC20
Watching Dx panel #CancerProgressNYC20 w/panelists incl @FoundationATCG VP David Fabrizio, Thrive Earlier Detection Chief Innovation Officer @c_lengauer, @gnshealthcare CEO Colin Hill, @freenome CSO Jimmy Lin, @NFCR Brian Jones, @GenomeProfiling CSO Adam Marsh, @OncimmuneECDT CSO
Chief Scientific Officer, Tariq Sethi on the panel at the virtual Cancer Progress by Cello Health Conference today discussing 'Next wave of diagnostics, including precision IO: early and smarter, the better to cure'. https://bit.ly/3fi4Kge #lungcancer #lungscreening #extratime
"Medical diagnostics — or tests as has become the colloquial over the last few weeks — are no different to sensors in race cars.".
Dr Adam M Hill considers how doctors make decisions and the information they need in the context of #COVID19 testing.
Making the right decisions with the right tools
A place where words matter
bit.ly
CEO Adam Hill shares his thoughts on #COVID19's likely impact on the practice of #diagnosis on @Medium. Read the first post here: @Tech_Trender
#Testing #Covid19UK #Covid_19
We are living in testing times
A place where words matter
link.medium.com
CEO Dr Adam Hill puts down his thoughts on #COVID19's likely impact on the practice of #diagnosis. Read the full
@Medium post here:
@Tech_Trender #Testing #Covid19UK #Covid_19
We are living in testing times
A place where words matter
link.medium.com
Oncimmune Board member Richard Sharp is to to advise the chancellor on the COVID-19 pandemic.
Coronavirus: Sunak’s ex-Goldman boss to be adviser on crisis
Richard Sharp, who mentored Rishi Sunak at Goldman, is to advise the chancellor on the COVID-19 pandemic, Sky News learns.
bit.ly
Gallery
